Trial Profile
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Feladilimab (Primary) ; Tremelimumab (Primary) ; Cetuximab; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms INDUCE-2
- Sponsors GlaxoSmithKline; GSK
- 13 Feb 2024 Results for safety and efficacy, published in the Cancer Immunology Immunotherapy
- 04 Oct 2021 Status changed from active, no longer recruiting to completed.
- 17 May 2021 Planned End Date changed from 30 Jul 2021 to 31 Aug 2022.